CDC-RFA-DD-23-0003: Pregnant People-Infant Linked Longitudinal Surveillance
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control - NCBDDD notices from 2023.
Centers for Disease Control - NCBDDD offered grants to any type of organization. It expected to make about 22 awards worth $5.0 million in total. Applications closed on April 10, 2023.
From the official notice on Grants.gov, last changed February 13, 2023. Checked November 7, 2026.
- Total funding$5.0 million
- Expected awards22
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | February 9, 2023 |
|---|---|
| Deadline | April 10, 2023 |
| Archived by Grants.gov | May 10, 2023 |
Who can apply
This opportunity was open to any type of organization.
All 16 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
Eligible applicants must have the public health authority, legislative mandate or otherwise show legal access to the requisite data to conduct clinic or population-based surveillance. This authority allows unique and specific access to datasets from multiple data sources that are required to implement the activities outlined in this NOFO. This may be an MOU, letter of support, or other legal documentation to demonstrate public health authority, legislative mandate, or legal access to the data. Eligible applicants must document this authority in "Other Attachment Forms" with attachment name "Legal Authority" as a PDF uploaded to www.grants.gov. CDC will consider any application that does not include this required documentation as non-responsive, and it will receive no further review. A Bona Fide Agent is an agency/organization identified by the state as eligible to submit an application under the state eligibility in lieu of a state application. If applying as a Bona Fide Agent of a state government, a letter from the state government as documentation of the status is required and should be submitted under "Other Attachment Forms" with attachment name "Bona Fide Agent.” If the Bona Fide Agent attachment does not specify legal authority, the applicant must include an attachment named "Legal Authority" in "Other Attachment Forms". The NOFO has three components: A, B, and C. Eligible applicants may only apply for Component A, Component B, or Component C. If an applicant submits multiple applications, all applications will be deemed non-responsive, and none will receive further review. In the “Descriptive Title of Applicant’s Project” on the SF-424 form, applicants must identify the component to which they are applying.
Is this a realistic fit?
- Most of the program's money (29% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
CDC proposes to allocate funds to implement Notice of Funding Opportunity (NOFO) DD-23-0003, Pregnant People-Infant Linked Longitudinal Surveillance. The project period will be four years, with 4, 12-month budget periods and an anticipated project start date of September 30, 2023. The purpose of this NOFO is to sustain, improve, and expand surveillance efforts from entities that have data systems to identify pregnant people-infant linked longitudinal data to ensure timely reporting of key exposures and outcomes that impact pregnant people and infants, to improve data quality and share evolving outcome data, to innovate clinical strategies, and to build a strong collaborative network. Priority exposures and outcomes of public health interest may include, but are not limited to, medication for opioid use disorder, cytomegalovirus, neonatal abstinence syndrome, stillbirths, and other conditions that may have serious public health impacts on pregnant people and infants. CDC will also fund entities with informatics expertise to advance interoperability, evaluate data quality, and disseminate data through visualizations. Furthermore, this network could be leveraged for emerging, reemerging, and persistent public health threats to pregnant people and infants.
Who has won Birth Defects and Developmental Disabilities - Prevention and Surveillance grants before
From fiscal 2021 to 2025, Birth Defects and Developmental Disabilities - Prevention and Surveillance (93.073) awarded $94.9 million across 102 grant awards, an average of $930,644 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Johns Hopkins University | Maryland | 2 | $5.7 million |
| University of North Carolina at Chapel Hill | North Carolina | 4 | $4.9 million |
| University of Texas at Austin | Texas | 2 | $4.2 million |
| Massachusetts Department of Public Health | Massachusetts | 3 | $3.6 million |
| The University of Iowa | Iowa | 3 | $3.5 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is CDC-RFA-DD-23-0003 still open?
No. It closed on April 10, 2023. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for Pregnant People-Infant Linked Longitudinal Surveillance?
Centers for Disease Control - NCBDDD accepted applications from any type of organization. The notice adds further conditions, so read its eligibility section.
What is the deadline for Pregnant People-Infant Linked Longitudinal Surveillance?
Closed April 10, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $5.0 million in total across about 22 awards.
Who has won Birth Defects and Developmental Disabilities - Prevention and Surveillance grants before?
The largest recipients over five fiscal years were The Johns Hopkins University, University of North Carolina at Chapel Hill, University of Texas at Austin. The program made 102 awards worth $94.9 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)